Follow the Money: SARM1 Inhibitor for ALS, Mental Health, AI

By Integrative Practitioner Staff 

Handspring grows its workforce, partnerships, and reach to offer virtual mental health treatment for youth and families; Supply6 plans to enhance its product innovation, clinical research, and digital experience; and more. 

$73.8M: Series B for SARM1 Inhibitor for ALS Treatment 

Nura Bio announced the completion of a $73.8 million Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs. The proceeds will fund the development of Nura Bio’s clinical pipeline, including the phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients. NB-4746 has been shown to prevent axon degeneration driven by the SARM1 protein, providing neuroprotection in multiple preclinical models of nerve injury and disease, including ALS. In a phase 1 study in healthy volunteers, NB-4746 demonstrated a favorable safety profile and achieved target plasma and cerebrospinal fluid exposure levels. Press release.  

$19M: Series B for Behavioral Health Model for Youth 

Handspring picked up $19 million in a Series B funding to grow its clinician workforce, expand value-based care partnerships with payers, and broaden its geographic reach. Health offers a virtual mental health clinic for youth and families, purpose-built around evidence-based care and ongoing training and support for clinicians. Handspring clinicians treat children and teens between the ages of eight to 17, as well as young adults 18 to 26-years-old, and clinicians are trained in treating anxiety, depression, OCD, ADHD, trauma, and other mental health challenges. The care model also includes ongoing training and support for parents who are viewed as an essential part of the therapy process. This support encompasses parent training sessions using behavioral parent training (BPT). Press release. 

$17M: Series B for Mental Health Care Expansion 

Vanna Health has secured $17 million in a Series B funding round. The company will use the capital to expand its clinical footprint, bolster its technology infrastructure, and bring its care model to new markets. The company’s new mission is to steer the company toward new automation and predictive analytics capabilities to inform care in real-time, which some of the new capital will be put toward. Press release.  

$7M: Series A for AI-Powered Preventative Health Platform 

SuperLiving has secured $7 million in a Series A funding round to enhance its AI-powered preventive health platform. The company provides a personalized wellness ecosystem that serves users through an AI companion capable of tracking lifestyle metrics and offering tailored health recommendations. SuperLiving plans to use the new capital to strengthen its AI infrastructure, expand its regional language content ecosystem, and accelerate product development. Press release.  

$5M: Financing for Supplement Expansion 

Supply6 has raised $5 million in a financing round that will be used toward product innovation, clinical research, supply chain capabilities, digital experience, and expansion across direct-to-consumer, marketplaces, and quick-commerce channels.  Supply6 offers daily supplements across vitamins, hydration, and fiber categories. Its flagship product, Supply6 360, combines over 63 ingredients, including probiotics, micronutrients, and adaptogens. Press release.